Prospective oral mucositis audit : oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy : european blood and marrow transplantation mucositis advisory group

McCann, Shaun

doi:10.1200/jco.2007.13.6028

Prospective oral mucositis audit : oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy : european blood and marrow transplantation mucositis advisory group

Date Issued

2008-01-01

Author(s)

Blijlevens, Nicole

Schwenkglenks, Matthias

Bacon, Pamela

D'Addio, Alessandra

Einsele, Hermann

Maertens, Johan

Niederwieser, Dietger

Rabitsch, Werner

Roosaar, Ann

Ruutu, Tapani

Schouten, Harry

Stone, Rebecca

Vokurka, Samuel

Quinn, Barry

McCann, Shaun

DOI

10.1200/jco.2007.13.6028

Abstract

The Prospective Oral Mucositis Audit assessed the incidence, duration, and determinants of severe oral mucositis (OM; WHO oral toxicity scale grades 3 to 4) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) receiving high-dose conditioning chemotherapy before autologous stem-cell transplantation.